Glenmark Pharmaceuticals Limited hosted its Investor Day 2026 in Mumbai on Tuesday, June 9, 2026. The presentation, filed with the stock exchanges under Ref. No. 21/26-27, outlined the company's strategic roadmap to transform into a global, innovation-led pharmaceutical company.

Strategic Roadmap and Long-term Vision (2026-2035)

The company's vision is to become a leading global, innovation-driven company. The strategic roadmap is divided into two phases:

  • 2026-2030: Focus on achieving therapy area dominance in Dermatology, Respiratory, and Oncology in India & Emerging Markets. Scale up the generic business in the US through Respiratory and Injectable launches. Gain scale in Europe across generics and Specialty products. Target 3-4 multispecific antibodies from IGI to enter clinical development and close additional new partnerships.
  • 2030-2035: Focus on the global commercialization of 1-2 multispecific innovative products from IGI's Oncology portfolio. Achieve a leadership position in Respiratory and Injectables in the US generics market. Scale up Glenmark's presence in Innovative Dermatology and Respiratory.

Capital Allocation and Strategic Focus

The capital allocation strategy is aimed at value-chain enhancement. Key investment decisions include:

  • Expanding presence in India & Emerging Markets across branded products.
  • Strengthening the existing Respiratory & Injectable platform in the USA.
  • Gaining scale in core European markets.
  • Expanding the commercial build-out for Innovative Oncology in India & Emerging Markets.
  • Enhancing the Specialty Dermatology & Respiratory portfolio in Europe.
  • Evaluating global in-licensing opportunities for novel assets in development.
  • Continuing investments in the BEAT® Platform to discover novel multispecific antibodies in Oncology, targeting 1 IND filing every year starting FY27.

Global Business and Regional Performance

Glenmark's business is well-diversified globally, with a focus on three key therapeutic areas: Respiratory, Dermatology, and Oncology.

  • India: Ranked 3rd in the Indian Pharmaceutical Market (IPM) as per IQVIA MAT March 2026. Initiatives include scaling up the Oncology franchise, expanding the field-force, launching differentiated products in Chronic Respiratory & Cardiac, driving turnaround in Diabetes with GLIPIQ®, and expanding OTC/DTC verticals.
  • Emerging Markets: Targeted as the fastest-growing market. Strategy involves strengthening Oncology front-end capabilities, expanding field-force in Respiratory & Dermatology, strengthening geographic reach, and focusing on commercial execution of key brand launches.
  • Europe: Strategy focuses on launching additional Respiratory products to gain leadership, strengthening RYALTRIS® position, successfully launching WINLEVI® and HILKOTA® in Dermatology, and pursuing in-licensing and M&A.
  • North America (USA): Ranked 8th among U.S. Generic Pharmaceutical Companies (Rx Only) as of IQVIA LTM March 2026. Strategy includes continuing launch momentum in Respiratory (2-3 launches in FY27e, filing 2-3 products annually), scaling Monroe injectables through capacity expansion over 3-5 years, building branded presence with RYALTRIS®, evaluating Dermatology as a branded platform, and expanding Institutional and OTC verticals.

Key Therapeutic Areas and Product Portfolio

  • Respiratory: Ranked 3rd in India and Russia. Eight products launched in Europe. First generic launch of FloVent® 44mcg in the US. RYALTRIS® is commercialized in 56 markets globally as of April 2026, with cumulative global sales of US$300 million as of FY26.
  • Dermatology: Ranked 2nd in India and 8th in Russia. Expanding OTC/DTC portfolio and Specialty portfolio in Europe with WINLEVI® and HILKOTA®.
  • Oncology: Ranked among Top 5 Indian companies. Building a commercial front-end to support innovative launches.

Innovative Product Launches and Pipeline

The company highlighted its pipeline of innovative brands driving future growth, with expected peak sales for its respiratory portfolio estimated at US$700-800 million annually globally over the next 7-8 years.

| Product | Indication | Key Regions | Launch Timelines |

| WINLEVI® (Clascoterone) | Acne Vulgaris | Europe, South Africa | Launched |

| HILKOTA® | Plaque Psoriasis | Global | FY27 |

| TEVIMBRA® (Tislelizumab-jsgr) | 1L/2L NSCLC, ESCC | India & Emerging Markets | Launched |

| BRUKINSA® (Zanubrutinib) | CLL, other B-cell malignancies | India | Launched |

| Aumolertinib | NSCLC | India & Emerging Markets | FY27 |

| Trastuzumab Rezetecan | HER2+ tumours (e.g., NSCLC, BC) | India & Emerging Markets | FY29 |

Innovation Update (IGI)

Innovative Genetics Inc. (IGI), the company's innovation arm, is a clinical-stage biotechnology company focused on next-generation multispecific antibodies in Oncology using its proprietary BEAT® platform.

  • ISB 2001 (ABBV-2001): A CD38 x BCMA x CD3 trispecific T-cell engager for Multiple Myeloma, partnered with AbbVie. In Phase 1 TRIgnite-1 study; >145 subjects dosed to date. Safety and efficacy data are consistent with ASCO 2025 presentation and continue to be promising. Goal is to determine Recommended Phase 2 Dose (RP2D) by Q4 2026. A Phase 1/2 combination study is planned for Q3 2026.
  • ISB 2301: A first-in-class, penta-specific multispecific immune cell activator targeting solid tumors. It targets three tumour-associated antigens (TAAs) to activate T cells and NK cells. IGI intends to submit an IND application later in CY26.
  • Funding & Strategy: IGI is poised to be self-sustaining through milestone payments from partnerships, new licensing deals, royalties, and a potential IPO. It targets an average annual investment of ~US$70 million and aims for 1 IND filing every year.

Financial Performance and Targets

Anurag Mantri, Executive Director & Global CFO, presented the company's financial commitments and achievements against its Investor Day 2022 guidance.

| Criteria | Investor Day 2022 Guidance | Achievement |

| Revenue Growth | 10-12% CAGR over 3-4 years | ~12% CAGR between FY22-FY26 |

| Branded Business Contribution | ~2/3rd of revenue from branded markets | >60% revenue from branded markets (on track) |

| Innovative Portfolio Launch | Commercial launch of 1 innovative asset | Launched WINLEVI® (Dermatology), TEVIMBRA®, BRUKINSA® (Oncology) |

| EBITDA Margin | 23% by FY27 | 21-22% guidance for FY27e (post growth investments) |

| ROCE | 23% by FY27 | >23% in FY27e |

| IGI Funding | Ensure IGI is self-funded | Achieved via ISB 2001 licensing deal with AbbVie |

| Net Debt | Zero net debt by FY26 | Achieved zero gross debt as of FY26 |

Medium-Term Financial Outlook (FY27-FY28)

The company provided a well-defined path to deliver shareholder value:

  • Growth: Target 13-15% revenue CAGR, driven by broad-based growth with greater contribution from branded markets.
  • Profitability: Target ~1% margin improvement in FY28 through operating leverage from growth initiatives with shorter payback periods.
  • Investments: Working capital to be structurally below industry average. Selective CAPEX and M&A will be ROCE-gated to support long-term growth.
  • Return Ratios: Continuously target >23% ROCE and >20% ROE. The company commits to maintaining a net cash position post all strategic actions.

Capital Structure Impact

The disclosure highlights a strengthened balance sheet with zero gross debt as of FY26, providing financial flexibility for future growth initiatives.